Status:
COMPLETED
Study to Investigate the Efficacy and Safety of QGE031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU)
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Chronic Spontaneous Urticaria
Eligibility:
All Genders
12-17 years
Phase:
PHASE2
Brief Summary
This clinical study was designed to evaluate the pharmacokinetics, safety and efficacy of ligelizumab in children from 12 to \< 18 years of age, with chronic spontaneous urticaria (CSU). The participa...
Detailed Description
This was a Phase IIb dose-finding, randomized, double-blind, parallel-group, placebo-controlled, multicenter study in adolescent patients. The study consisted of 3 distinct study periods: Screening, T...
Eligibility Criteria
Inclusion
- Parent or legal guardian's written informed consent and child's assent, if appropriate, must be obtained before any study related activity or assessment is performed. Of note, if the subject reaches age of consent (age as per local law) during the study, they will also need to sign the corresponding study ICF (Informed Consent Form) at the next study visit.
- Male and female adolescent patients aged ≥ 12 to \<18 years at the time of screening.
- Diagnosis of CSU refractory to approved doses of H1-antihistamines at the time of randomization, as defined by all of the following:
- The presence of itch and hives for at least 6 consecutive weeks at any time prior to enrollment despite current use of non-sedating H1-antihistamines during this time period
- UAS7 score (range 0 - 42) ≥ 16 and HSS7 (range 0 - 21) ≥ 8 during 7 days prior to randomization (Day 1)
- In-clinic UAS ≥ 4 on at least one of the screening visit days or Day 1 or a medical record of the presence of hives (confirmed and documented by a physician); patients must have been on H1-antihistamines for treatment of CSU at the time of in-clinic UAS at screening visit and/or time of the medical record of hives (for at least 3 days prior to the in-clinic UAS or medical record) • Patients must have been on H1-antihistamines for treatment of CSU for at least the 3 consecutive days immediately prior to the first screening visit and must have documented current use on the day of the initial screening visit
- CSU diagnosis for ≥ 6 months
- Willing and able to complete a daily symptom e-Diary for the duration of the study and adhere to the study visit schedules.
- Demonstration of compliance with the e-Diary: patients should not have had any missing e-Diary entries in the 7 days prior to randomization. Re-screening may be considered.
Exclusion
- Clearly defined underlying etiology for chronic urticarias other than CSU. This includes the following:
- Inducible urticaria: urticaria factitia, cold-, heat-, solar-, pressure-, delayed pressure-, aquagenic-, cholinergic-, or contact-urticaria
- Diseases with possible symptoms of urticaria or angioedema such as urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa), and hereditary or acquired angioedema (e.g., due to C1 inhibitor deficiency)
- Any other skin disease associated with chronic itching that might confound the study evaluations and results (e.g. atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis etc.)
- Previous exposure to omalizumab
- History of anaphylaxis
Key Trial Info
Start Date :
August 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 3 2021
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT03437278
Start Date
August 1 2018
End Date
February 3 2021
Last Update
April 29 2022
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina, S2000BRH
2
Novartis Investigative Site
Bahía Blanca, Argentina, B8000JRB
3
Novartis Investigative Site
Buenos Aires, Argentina, C1125ABE
4
Novartis Investigative Site
Brussels, Belgium, 1200